Company intelligence

Shionogi

Japanese pharmaceutical company developing prescription drugs, infectious disease therapies, and specialty medicines, including a former sleep apnea drug joint venture with Apnimed.

BiotechPublic · 4507.TOsaka, JapanFounded 1919Founders: Gisaburō ShionoWebsite ↗See connections →
Last verified Jul 31, 2026

Shionogi at a glance

Founded
1919[1]
Headquarters
Osaka, Japan[2]
  1. [1] Founded: Wikidata (retrieved September 27, 2026)
  2. [2] Headquarters: Wikidata (retrieved September 27, 2026)

Is this your company? Get featured or correct your listing →

Company Snapshot

Shionogi is a biotech company, based in Osaka, Japan, founded 1919 by Gisaburō Shiono.

Latest Pulse

  1. Apnimed Launches $150M IPO For First Sleep Apnea PillShionogi-backed Apnimed launched a $150 million IPO for its once-daily obstructive sleep apnea pill AD109, targeting a Thursday pricing ahead of a Friday NASDAQ debut.→
  2. Apnimed Files for Nasdaq IPO on First Oral Sleep Apnea PillApnimed, a Shionogi-backed clinical-stage biotech, filed for a Nasdaq IPO under ticker APMD as its lead drug candidate Oxnimbi -- the first investigational oral pill for obstructive sleep apnea -- awaits an FDA decision expected in Q1 2027.→

Coverage Timeline

newest first
  1. Jul 27, 2026IPOApnimed Launches $150M IPO For First Sleep Apnea Pillup to $150M IPO→
  2. Jul 10, 2026IPOApnimed Files for Nasdaq IPO on First Oral Sleep Apnea Pill→

All Coverage

IPO

Apnimed Launches $150M IPO For First Sleep Apnea Pill

Illustration for: Apnimed Launches $150M IPO For First Sleep Apnea Pill
IPOup to $150M IPO

Apnimed Launches $150M IPO For First Sleep Apnea Pill

Shionogi-backed Apnimed launched a $150 million IPO for its once-daily obstructive sleep apnea pill AD109, targeting a Thursday pricing ahead of a Friday NASDAQ debut.

IPO

Apnimed Files for Nasdaq IPO on First Oral Sleep Apnea Pill

Illustration for: Apnimed Files for Nasdaq IPO on First Oral Sleep Apnea Pill
IPO

Apnimed Files for Nasdaq IPO on First Oral Sleep Apnea Pill

Apnimed, a Shionogi-backed clinical-stage biotech, filed for a Nasdaq IPO under ticker APMD as its lead drug candidate Oxnimbi -- the first investigational oral pill for obstructive sleep apnea -- awaits an FDA decision expected in Q1 2027.

Related Companies

Same sector
Scribe TherapeuticsIambic TherapeuticsAttovia TherapeuticsApnimedEli LillyRetension Pharmaceuticals

Shionogi FAQ

When was Shionogi founded and where is it based?

Shionogi was founded in 1919 and is headquartered in Osaka, Japan, according to Wikidata.